Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) treatment.
Kunzmann
V
V
Ruediger
T
T
Hallek
M
M
Mueller-Hermelink
H K
HK
Wilhelm
M
M
D000368:Aged; D000371:Agglutination; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001808:Blood Vessels / Q000473:pathology; D016207:Cytokines / Q000096:biosynthesis; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications* / Q000188:drug therapy; D018921:Leukostasis / Q000209:etiology* / Q000473:pathology; D016403:Lymphoma, Large B-Cell, Diffuse / Q000150:complications* / Q000473:pathology; D008297:Male; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D016207:Cytokines; D000069283:Rituximab